To further explore the target proteins of EpOME action in breast cancer cells, we treated breast cancer cells with medium containing 12(13)-EpOME, as well as a control group treated with blank medium, with three replicates in each group, and collected the cells, lysed them to extract the total proteins, and enzymatically cleaved them into peptides, which were then subjected to proteomics assay using the iTRAQ technology.